Back to Search Start Over

Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study

Authors :
Simon P Bach
Alexandra Gilbert
Kristian Brock
Stephan Korsgen
Ian Geh
James Hill
Talvinder Gill
Paul Hainsworth
Matthew G Tutton
Jim Khan
Jonathan Robinson
Mark Steward
Christopher Cunningham
Bruce Levy
Alan Beveridge
Kelly Handley
Manjinder Kaur
Natalie Marchevsky
Laura Magill
Ann Russell
Philip Quirke
Nicholas P West
David Sebag-Montefiore
Gina Brown
Peter Antonio
Alex Vince
Nick Hilken
Chakanaka Sidile
Adrian Wilcockson
Richard Peto
Tom Crosby
Brendan Moran
Julie Olliff
Katti Ashok
Simone Slawik
Andrew Smethurst
Rajaram Sripadam
Veena Tagore
Monica Terlizzo
Bearn Philip
Robert Davies
Susan Dodd
Sharadah Essapen
Pasha Nisar
Alexandra Stewart
Jonathan Trickett
Bansal Ashish
Peter Billings
Palanichamy Chandran
Conor Corr
Edward Favill
Simon Gollins
Peter Marsh
Andrew Maw
Rakha Neupane
Ramesh Rajagopal
Rachel Cooper
John Griffith
Paul Hatfield
Andy Lowe
Julian Ostrowski
Rhian Simpson
Richard Adams
Robert Bleehen
Michael Davies
Meleri Morgan
Darren Boone
Nicola Lacey
Ian Seddon
Bruce Sizer
Helen Stunell
Shaobin Wu
Maher Hadaki
Dominic Blunt
Susan Cleator
Ara Darzi
Robert Goldin
Paul Ziprin
Mike Dobson
Mark Pitt
Shabbir Susnerwala
Deborah Williamson
Georgina Howarth
Stephen Lee
Paul Wright
Tim Hoare
Alan Horgan
Fiona McDonald
Stephanie Needham
John Scott
Timothy Simmons
Debashis Biswas
James Hernon
Gaurav Kapur
Sandeep Kapur
James Sington
Christopher Speakman
William Stebbings
Stuart Williams
Madhavi Adusumalli
Anil Agarwal
David Borowski
Dharmendra Garg
Mohammed Hegab
Catherine Hobday
Veena Rao
Jyotsna Shrimankar
Mohamed Tabaqchali
David Wilson
Oliver Jones
Neil Mortensen
Andrew Slater
Aron Szuts
Lai Wang
Bryan Warren
Andrew Weaver
Mukhtar Ahmad
Julian Alexander
Maxine Flubacher
David Tarver
Suhail Baluch
Richard Beable
David Cowlishaw
Antony Higginson
Prokopios Vogiatzis
Neil Cruickshank
Howard Joy
David Peake
Ulises Zanetto
Mark Saunders
Arthur Sun-Myint
Mark Teo
Arthur Allan
John Glaholm
Mark Goldstein
Rahul Hejmadi
Gerald Langman
Dion Morton
Cyril Nelson
Deborah Tattersall
Stephen Falk
Robert Longman
Huw Roach
Jamshed Shabbir
Golda Shelley-Fraser
Michael Thomas
Neil Cripps
Yasser Haba
Guy Harris
Max Hookway
Jay Simson
Angela Skull
Tijani Umar
National Institute of Health Research
Source :
The Lancet. Gastroenterology & Hepatology
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Summary Background Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting patients to a randomised trial comparing an organ-preserving strategy with total mesorectal excision. Methods TREC was a randomised, open-label feasibility study done at 21 tertiary referral centres in the UK. Eligible participants were aged 18 years or older with rectal adenocarcinoma, staged T2 or lower, with a maximum diameter of 30 mm or less; patients with lymph node involvement or metastases were excluded. Patients were randomly allocated (1:1) by use of a computer-based randomisation service to undergo organ preservation with short-course radiotherapy followed by transanal endoscopic microsurgery after 8–10 weeks, or total mesorectal excision. Where the transanal endoscopic microsurgery specimen showed histopathological features associated with an increased risk of local recurrence, patients were considered for planned early conversion to total mesorectal excision. A non-randomised prospective registry captured patients for whom randomisation was considered inappropriate, because of a strong clinical indication for one treatment group. The primary endpoint was cumulative randomisation at 12, 18, and 24 months. Secondary outcomes evaluated safety, efficacy, and health-related quality of life assessed with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ C30 and CR29 in the intention-to-treat population. This trial is registered with the ISRCTN Registry, ISRCTN14422743. Findings Between Feb 22, 2012, and Dec 19, 2014, 55 patients were randomly assigned at 15 sites; 27 to organ preservation and 28 to radical surgery. Cumulatively, 18 patients had been randomly assigned at 12 months, 31 at 18 months, and 39 at 24 months. No patients died within 30 days of initial treatment, but one patient randomly assigned to organ preservation died within 6 months following conversion to total mesorectal excision with anastomotic leakage. Eight (30%) of 27 patients randomly assigned to organ preservation were converted to total mesorectal excision. Serious adverse events were reported in four (15%) of 27 patients randomly assigned to organ preservation versus 11 (39%) of 28 randomly assigned to total mesorectal excision (p=0·04, χ2 test). Serious adverse events associated with organ preservation were most commonly due to rectal bleeding or pain following transanal endoscopic microsurgery (reported in three cases). Radical total mesorectal excision was associated with medical and surgical complications including anastomotic leakage (two patients), kidney injury (two patients), cardiac arrest (one patient), and pneumonia (two patients). Histopathological features that would be considered to be associated with increased risk of tumour recurrence if observed after transanal endoscopic microsurgery alone were present in 16 (59%) of 27 patients randomly assigned to organ preservation, versus 24 (86%) of 28 randomly assigned to total mesorectal excision (p=0·03, χ2 test). Eight (30%) of 27 patients assigned to organ preservation achieved a complete response to radiotherapy. Patients who were randomly assigned to organ preservation showed improvements in patient-reported bowel toxicities and quality of life and function scores in multiple items compared to those who were randomly assigned to total mesorectal excision, which were sustained over 36 months’ follow-up. The non-randomised registry comprised 61 patients who underwent organ preservation and seven who underwent radical surgery. Non-randomised patients who underwent organ preservation were older than randomised patients and more likely to have life-limiting comorbidities. Serious adverse events occurred in ten (16%) of 61 non-randomised patients who underwent organ preservation versus one (14%) of seven who underwent total mesorectal excision. 24 (39%) of 61 non-randomised patients who underwent organ preservation had high-risk histopathological features, while 25 (41%) of 61 achieved a complete response. Overall, organ preservation was achieved in 19 (70%) of 27 randomised patients and 56 (92%) of 61 non-randomised patients. Interpretation Short-course radiotherapy followed by transanal endoscopic microsurgery achieves high levels of organ preservation, with relatively low morbidity and indications of improved quality of life. These data support the use of organ preservation for patients considered unsuitable for primary total mesorectal excision due to the short-term risks associated with this surgery, and support further evaluation of short-course radiotherapy to achieve organ preservation in patients considered fit for total mesorectal excision. Larger randomised studies, such as the ongoing STAR-TREC study, are needed to more precisely determine oncological outcomes following different organ preservation treatment schedules. Funding Cancer Research UK.

Details

Language :
English
ISSN :
14422743 and 24681253
Database :
OpenAIRE
Journal :
The Lancet. Gastroenterology & Hepatology
Accession number :
edsair.doi.dedup.....0429cb08c4dbffa6cf68653420de5021